Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial

Blood

Volumn 132, Issue 4, 2018, Pages 393-404

  Cortes, Jorge E ^a   Kim, Dong Wook ^b   Pinilla Ibarz, Javier ^c   le Coutre, Philipp D ^d   Paquette, Ronald ^e   Chuah, Charles ^f   Nicolini, Franck E ^g   Apperley, Jane F ^h   Khoury, H Jean ⁱ   Talpaz, Moshe ^j   DeAngelo, Daniel J ^k   Abruzzese, Elisabetta ^l   Rea, Delphine ^m   Baccarani, Michele ⁿ   Müller, Martin C ^o,x   Gambacorti Passerini, Carlo ^p   Lustgarten, Stephanie ^q   Rivera, Victor M ^q   Haluska, Frank G ^q   Guilhot, François ^r,s   Deininger, Michael W ^t   Hochhaus, Andreas ^u   Hughes, Timothy P ^v   Shah, Neil P ^w   Kantarjian, Hagop M ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b The Catholic University of Korea   (South Korea)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e CEDARS SINAI MEDICAL CENTER   (United States)

^f DUKE NUS MEDICAL SCHOOL   (Singapore)

^g CENTRE HOSPITALIER LYON SUD   (France)

^h IMPERIAL COLLEGE LONDON   (United Kingdom)

ⁱ EMORY UNIVERSITY   (United States)

^j UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^k DANA FARBER CANCER INSTITUTE   (United States)

^l UNIVERSITY OF ROME TOR VERGATA   (Italy)

^m SAINT LOUIS HOSPITAL   (France)

ⁿ UNIVERSITY OF BOLOGNA   (Italy)

^o UNIVERSITY OF HEIDELBERG   (Germany)

^p UNIVERSITY OF MILANO BICOCCA   (Italy)

^q TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^r INSERM   (France)

^s POITIERS UNIVERSITY HOSPITAL   (France)

^t UNIVERSITY OF UTAH   (United States)

^u JENA UNIVERSITY HOSPITAL   (Germany)

^v UNIVERSITY OF ADELAIDE   (Australia)

^w UNIVERSITY OF CALIFORNIA   (United States)

^x Institute for Hematology and Oncology   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; NILOTINIB; PONATINIB; TRIACYLGLYCEROL LIPASE; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; PYRIDAZINE DERIVATIVE;

ABDOMINAL PAIN; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ADVANCED CANCER; AGED; ANGINA PECTORIS; ARTERY OCCLUSION; ARTHRALGIA; ARTICLE; BONE MARROW BIOPSY; CANCER SURVIVAL; CARDIOVASCULAR RISK; CHRONIC MYELOID LEUKEMIA; CLINICAL OUTCOME; CONSTIPATION; CYTOGENETICS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRY SKIN; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; HUMAN TISSUE; HYPERTENSION; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUTROPENIA; OVERALL SURVIVAL; PANCREATITIS; PHASE 2 CLINICAL TRIAL; PHILADELPHIA 1 CHROMOSOME; PNEUMONIA; PRIORITY JOURNAL; RASH; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM; VOMITING; CLINICAL TRIAL; DRUG EFFECT; DRUG RESISTANCE; GENETICS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SAFETY; SALVAGE THERAPY; TIME FACTOR; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMIDAZOLES; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PHILADELPHIA CHROMOSOME; PROGNOSIS; PYRIDAZINES; SAFETY; SALVAGE THERAPY; SURVIVAL RATE; TIME FACTORS; YOUNG ADULT;

EID: 85048250671     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-09-739086     Document Type: Article

References (39)

1. O’Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16(5): 401-412.
2. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872-884.
3. Iclusig [package insert]. Cambridge, MA: ARIAD Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; 2016.
4. Iclusig [summary of product characteristics]. Leatherhead, United Kingdom: ARIAD Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; 2017.
5. Cortes JE, Kim DW, Pinilla-Ibarz J, et al; PACE Investigators. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369(19):1783-1796.
6. Garg RJ, Kantarjian H, O’Brien S, et al. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term followup. Blood. 2009;114(20):4361-4368.
7. Ibrahim AR, Paliompeis C, Bua M, et al. Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy. Blood. 2010; 116(25):5497-5500.
8. Khoury HJ, Cortes JE, Kantarjian HM, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood. 2012; 119(15):3403-3412.
9. Hochhaus A, Pinilla-Ibarz J, Kim D-W, et al. Clinical impact of dose modification and dose intensity on response to ponatinib in patients with Philadelphia chromosome-positive leukemias. Poster presented at the annual meeting of the American Society of Clinical Oncology; 30 May to 3 June 2014; Chicago, IL. Poster 7084.
10. Knickerbocker R, Dorer DJ, Haluska FG, et al. Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients [abstract]. Blood. 2014;124(21). Abstract 4546.
11. Dorer DJ, Knickerbocker RK, Baccarani M, et al. Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients. Leuk Res. 2016;48:84-91.
12. Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008;26(19): 3204-3212.
13. Shah NP, Kim DW, Kantarjian H, et al. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica. 2010;95(2): 232-240.
14. Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007; 110(10):3540-3546.
15. Kantarjian HM, Giles FJ, Bhalla KN, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011;117(4): 1141-1145.
16. Tasigna [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2017.
17. Gambacorti-Passerini C, Brümmendorf TH, Kim DW, et al. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up. Am J Hematol. 2014; 89(7):732-742.
18. Lipton JH, Bryden P, Sidhu MK, et al. Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors. Leuk Res. 2015;39(1):58-64.
19. le Coutre PD, Giles FJ, Hochhaus A, et al. Nilotinib in patients with Ph1 chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia. 2012;26(6): 1189-1194.
20. Saglio G, Hochhaus A, Goh YT, et al. Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. Cancer. 2010; 116(16):3852-3861.
21. Gambacorti-Passerini C, Kantarjian HM, Kim DW, et al. Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. Am J Hematol. 2015;90(9):755-768.
22. Nicolini FE, Ibrahim AR, Soverini S, et al. The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. Haematologica. 2013;98(10):1510-1516.
23. Mauro MJ, Cortes JE, Kim DW, et al. Multivariate analyses of the clinical and molecular parameters associated with efficacy and safety in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph1 ALL) treated with ponatinib in the PACE trial [abstract]. Blood. 2012;120(21). Abstract 3747.
24. Deininger MW, Hodgson JG, Shah NP, et al. Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. Blood. 2016;127(6):703-712.
25. Lipton JH, Chuah C, Guerci-Bresler A, et al; EPIC Investigators. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17(5): 612-621.
26. Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012;367(22):2075-2088.
27. le Coutre PD, Kim D-W, Pinilla-Ibarz J, et al. Ponatinib in heavily pretreated patients with chronic phase chronic myeloid leukemia (CP-CML): management of adverse events (AEs) [abstract]. Blood. 2013;122(21). Abstract 1496.
28. Steegmann JL, Baccarani M, Breccia M, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30(8): 1648-1671.
29. Valent P, Hadzijusufovic E, Schernthaner GH, Wolf D, Rea D, le Coutre P. Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood. 2015;125(6):901-906.
30. Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med. 2016;375(15):1457-1467.
31. Stemhagen A, Adib D, Lustgarten S, McGarry L, Du Moulin R, Santillana S. The OMNI patient registry: a prospective observational registry to assess vascular safety in patients with CML and Ph1 ALL treated with ponatinib [abstract]. J Clin Oncol. 2017;35(suppl 15). Abstract TPS7073.
32. Loren CP, Aslan JE, Rigg RA, et al. The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear. Thromb Res. 2015;135(1):155-160.
33. Rea D, Mirault T, Cluzeau T, et al. Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia. Haematologica. 2014;99(7): 1197-1203.
34. Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol. 2006;24(3):484-490.
35. Amer MH. Cancer-associated thrombosis: clinical presentation and survival. Cancer Manag Res. 2013;5:165-178.
36. Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol. 2015; 33(35):4210-4218.
37. Douxfils J, Haguet H, Mullier F, Chatelain C, Graux C, Dogné JM. Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis. JAMA Oncol. 2016;2(5): 625-632.
38. Sprycel [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2017.
39. Cortes JE, Jean Khoury H, Kantarjian H, et al. Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib. Am J Hematol. 2016;91(6): 606-616.